EP0753062A4 - Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs - Google Patents
Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructsInfo
- Publication number
- EP0753062A4 EP0753062A4 EP95905220A EP95905220A EP0753062A4 EP 0753062 A4 EP0753062 A4 EP 0753062A4 EP 95905220 A EP95905220 A EP 95905220A EP 95905220 A EP95905220 A EP 95905220A EP 0753062 A4 EP0753062 A4 EP 0753062A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- constructs
- compound
- recombinant retroviruses
- packaging sequence
- sequence expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02025406A EP1298208B1 (en) | 1994-01-05 | 1995-01-05 | Ribozymes targeting a hiv tat sequence |
DK02025406T DK1298208T3 (en) | 1994-01-05 | 1995-01-05 | Ribozymes targeting an HIV tat sequence |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/178,082 US5712384A (en) | 1994-01-05 | 1994-01-05 | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
US178082 | 1994-01-05 | ||
US08/310,259 US6114167A (en) | 1994-01-05 | 1994-09-21 | Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence |
US310259 | 1994-09-21 | ||
PCT/IB1995/000050 WO1995018854A1 (en) | 1994-01-05 | 1995-01-05 | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02025406A Division EP1298208B1 (en) | 1994-01-05 | 1995-01-05 | Ribozymes targeting a hiv tat sequence |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0753062A1 EP0753062A1 (en) | 1997-01-15 |
EP0753062A4 true EP0753062A4 (en) | 1999-10-20 |
Family
ID=26873946
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95905220A Withdrawn EP0753062A4 (en) | 1994-01-05 | 1995-01-05 | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
EP02025406A Expired - Lifetime EP1298208B1 (en) | 1994-01-05 | 1995-01-05 | Ribozymes targeting a hiv tat sequence |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02025406A Expired - Lifetime EP1298208B1 (en) | 1994-01-05 | 1995-01-05 | Ribozymes targeting a hiv tat sequence |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP0753062A4 (en) |
JP (1) | JP3691849B2 (en) |
CN (1) | CN1267552C (en) |
AT (1) | ATE320487T1 (en) |
AU (1) | AU698730B2 (en) |
CA (1) | CA2180358A1 (en) |
DE (1) | DE69534864T2 (en) |
DK (1) | DK1298208T3 (en) |
ES (1) | ES2260376T3 (en) |
IL (1) | IL112261A (en) |
NO (1) | NO319376B1 (en) |
NZ (1) | NZ278432A (en) |
PT (1) | PT1298208E (en) |
WO (1) | WO1995018854A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020058636A1 (en) * | 1994-09-21 | 2002-05-16 | Geoffrey P. Symonds | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
WO1997007808A1 (en) * | 1995-08-25 | 1997-03-06 | The Regents Of The University Of California | Chimeric antiviral agents which incorporate rev binding nucleic acids |
US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
IL124636A0 (en) * | 1995-11-28 | 1998-12-06 | Univ Johns Hopkins Med | Conditionally replicating viral vectors and their use |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
CN1796556A (en) | 1998-03-20 | 2006-07-05 | 联邦科学和工业研究组织 | Control of gene expression |
WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
EP1229134A3 (en) | 2001-01-31 | 2004-01-28 | Nucleonics, Inc | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
CN101926824A (en) | 2001-07-10 | 2010-12-29 | 强生和强生研究有限公司 | The method that is used for the genetic modification hemopoietic progenitor cell is modified the application of cell with these |
US7994144B2 (en) | 2001-07-10 | 2011-08-09 | Johnson & Johnson Research Pty, Limited | Process for the preparation of a composition of genetically modified hematopoietic progenitor cells |
CN102841007A (en) * | 2012-09-05 | 2012-12-26 | 福建省农业科学院畜牧兽医研究所 | Semen diluent convenient to count duck sperms and application method thereof |
CN113549641B (en) * | 2021-06-29 | 2023-12-22 | 复旦大学 | Ribozyme-mediated polycistronic vector and construction method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
WO1994016736A1 (en) * | 1993-01-22 | 1994-08-04 | University Research Corporation | Localization of therapeutic agents |
EP0612844A2 (en) * | 1993-02-25 | 1994-08-31 | Ortho Pharmaceutical Corporation | Expression constructs containing HIV inhibitory antisense and other nucleotide sequences, retroviral vectors and recombinant retroviruses containing same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017211A1 (en) * | 1991-04-05 | 1992-10-15 | Edison Animal Biotechnology Center, Ohio University | Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences |
WO1995004818A1 (en) * | 1993-08-06 | 1995-02-16 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting human immunodeficiency virus replication |
-
1995
- 1995-01-05 PT PT02025406T patent/PT1298208E/en unknown
- 1995-01-05 JP JP51840395A patent/JP3691849B2/en not_active Expired - Fee Related
- 1995-01-05 ES ES02025406T patent/ES2260376T3/en not_active Expired - Lifetime
- 1995-01-05 EP EP95905220A patent/EP0753062A4/en not_active Withdrawn
- 1995-01-05 AU AU13912/95A patent/AU698730B2/en not_active Ceased
- 1995-01-05 AT AT02025406T patent/ATE320487T1/en not_active IP Right Cessation
- 1995-01-05 NZ NZ278432A patent/NZ278432A/en not_active IP Right Cessation
- 1995-01-05 DE DE69534864T patent/DE69534864T2/en not_active Expired - Lifetime
- 1995-01-05 EP EP02025406A patent/EP1298208B1/en not_active Expired - Lifetime
- 1995-01-05 DK DK02025406T patent/DK1298208T3/en active
- 1995-01-05 IL IL11226195A patent/IL112261A/en not_active IP Right Cessation
- 1995-01-05 CA CA002180358A patent/CA2180358A1/en not_active Abandoned
- 1995-01-05 WO PCT/IB1995/000050 patent/WO1995018854A1/en not_active Application Discontinuation
- 1995-01-05 CN CNB951919318A patent/CN1267552C/en not_active Expired - Fee Related
-
1996
- 1996-07-04 NO NO19962826A patent/NO319376B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
WO1994016736A1 (en) * | 1993-01-22 | 1994-08-04 | University Research Corporation | Localization of therapeutic agents |
EP0612844A2 (en) * | 1993-02-25 | 1994-08-31 | Ortho Pharmaceutical Corporation | Expression constructs containing HIV inhibitory antisense and other nucleotide sequences, retroviral vectors and recombinant retroviruses containing same |
Non-Patent Citations (5)
Title |
---|
CHEN, C.-J. ET AL.: "Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - potential effectiveness against most presently sequenced HIV-1 isolates", NUCLEIC ACIDS RESEARCH., vol. 20, 11 September 1992 (1992-09-11), pages 4581 - 4589, XP002111362, ISSN: 0305-1048 * |
HAN, L. ET AL.: "Inhibition of moloney murine leukemia virus-induced leukemia in transgenic mice expressing antisense RNA complementary to the retroviral packaging sequences", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 88, May 1991 (1991-05-01), pages 4313 - 4317, XP002111360, ISSN: 0027-8424 * |
LO, S. ET AL.: "Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA", VIROLOGY., vol. 190, 1992, pages 176 - 183, XP002111361, ISSN: 0042-6822 * |
ROSSI J J ET AL: "RIBOZYMES AS ANTI-HIV-1 THERAPEUTIC AGENTS: PRINCIPLES, APPLICATIONS, AND PROBLEMS", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, no. 2, 1 February 1992 (1992-02-01), pages 183 - 189, XP002026934, ISSN: 0889-2229 * |
YU M ET AL: "PROGRESS TOWARDS GENE THERAPY FOR HIV INFECTION", GENE THERAPY, vol. 1, no. 1, January 1994 (1994-01-01), pages 13 - 26, XP002050715, ISSN: 0969-7128 * |
Also Published As
Publication number | Publication date |
---|---|
IL112261A0 (en) | 1995-03-30 |
AU698730B2 (en) | 1998-11-05 |
NZ278432A (en) | 1998-06-26 |
CN1267552C (en) | 2006-08-02 |
CA2180358A1 (en) | 1995-07-13 |
PT1298208E (en) | 2006-10-31 |
JPH09508004A (en) | 1997-08-19 |
EP1298208B1 (en) | 2006-03-15 |
ATE320487T1 (en) | 2006-04-15 |
EP0753062A1 (en) | 1997-01-15 |
AU1391295A (en) | 1995-08-01 |
IL112261A (en) | 2005-08-31 |
JP3691849B2 (en) | 2005-09-07 |
NO962826L (en) | 1996-08-27 |
NO319376B1 (en) | 2005-07-25 |
ES2260376T3 (en) | 2006-11-01 |
DE69534864D1 (en) | 2006-05-11 |
WO1995018854A1 (en) | 1995-07-13 |
EP1298208A3 (en) | 2004-01-07 |
NO962826D0 (en) | 1996-07-04 |
DK1298208T3 (en) | 2006-07-24 |
EP1298208A2 (en) | 2003-04-02 |
DE69534864T2 (en) | 2007-02-22 |
CN1145638A (en) | 1997-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL112261A0 (en) | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs | |
KR960703170A (en) | ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTIC USE THEREOF IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION | |
AU6871398A (en) | Method for enhancing expression of a foreign or endogenous gene product in pla nts | |
WO1996019568A3 (en) | Stabilized ribozyme analogs | |
CY1106513T1 (en) | TRIPLE LENTINOIC DNA AND VEHICLES AND RECOMBINANT CELLS CONTAINING TRIPLE LENTINOIC DNA | |
HUP0204199A2 (en) | Transport vectors | |
FI946201A (en) | Self-stabilized oligonucleotides as therapeutic agents | |
CA2418442A1 (en) | Novel helper functions for recombinant vector production | |
WO1999041402A3 (en) | Targeting of genetic vaccine vectors | |
AU7189394A (en) | Retroviral vector for the transfer and expression of genes for therapeutical purposes in eucaryotic cells | |
WO1998056937A3 (en) | Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus | |
WO1998039463A3 (en) | Lentivirus based vector and vector system | |
IL133544A0 (en) | Lag-3 splice variants, their preparation and use | |
DK0630409T3 (en) | Defect-packing non-oncovirus vectors based on MPMV | |
PT835137E (en) | ENCAPSULATED CELLS PRODUCING VIRAL PARTICLES | |
IL117194A0 (en) | Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them | |
WO1999028439A3 (en) | Erythrovirus and its applications | |
NO995858L (en) | New class of cationic nucleic acid transfer agents | |
CA2167630A1 (en) | cDNA of DOCK180 Gene and DOCK180 Protein | |
WO2004003209A3 (en) | Nucleic acid isolated from the 5' non translated region (5'ntr) end of the human fgf-1 gene having ires activity | |
RU94006028A (en) | DNA, VECTOR, PROTEIN, CELLS, PLANTS AND SEEDS | |
MX9708943A (en) | Polyphenol oxidase genes from lettuce and banana. | |
NO945020L (en) | Self-stabilizing oligonucleotides as therapeutic agents | |
EP0828006A3 (en) | Use of cis- and/or trans-elements to enhance the efficiency of parvoviral vector transduction, integration and/or transgene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960731 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GENE SHEARS PTY LIMITED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GENE SHEARS PTY LIMITED |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19990903 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020305 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20021119 |